Medivir’s CEO increases his shareholding in the company


Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the company’s CEO,
Niklas Prager, has bought 10,000 class B shares in Medivir at an acquisition
price of approximately SEK 825.000. The share purchase has occurred within the
framework of an insurance arrangement and will consequently be made public
through this press release and not be reported to the Swedish Financial
Supervisory Authority’s insider register.

For more information please contact:
Niklas Prager, CEO Medivir AB, phone +46 (0)8-407 64 30.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a growing portfolio of specialty care
pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm
Mid Cap List.

Attachments

05121961.pdf